tadalafil has been researched along with Cardiovascular Diseases in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Barberà, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Hoeper, MM; Langley, J; McLaughlin, VV; Oudiz, RJ; Peacock, AJ; Rosenkranz, S; Rubin, LJ; Simonneau, G; Vachiery, JL | 1 |
| Dhaun, N; Farrah, TE; Tzoumas, N; Webb, DJ | 1 |
| Akinsal, EC; Baydilli, N; Selvi, I | 1 |
| Chiba, F; Iwase, H; Nagasawa, S; Saka, K; Torimitsu, S; Yajima, D; Yamagishi, Y; Yamaguchi, R | 1 |
| Bulygin, KV; Galimov, SN; Galimova, EF; Gaysina, GG; Nikitina, IL; Pavlov, VN | 1 |
| Ioakeimidis, N; Kostis, JB | 1 |
| Liu, KF | 1 |
| Liu, Y | 1 |
| Athyros, V; Doumas, M; Katsiki, N; Lazaridis, A | 1 |
| Brock, GB; Büttner, H; Esler, A; Maggi, M; Mulhall, JP; Oelke, M; Rosenberg, MT; Vlachopoulos, C | 1 |
| Awadin, WF; El-Shafei, RA; Elseady, YY; Elshal, MF; Saleh, RM; Wehaish, FE | 1 |
| Banerjee, SK; Katare, PB | 1 |
| Ducobu, J; Hauzeur, C; Ramal, A; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K | 1 |
| Tostain, J | 1 |
| De Berardis, G; Franciosi, M; Morelli, P; Nicolucci, A; Pamparana, F; Pellegrini, F; Tognoni, G | 1 |
| Katz, A | 1 |
| Corona, G; Fusco, F; Mondaini, N; Razzoli, E; Rossi, A; Ungar, A | 1 |
| Costabile, RA; Lowe, G | 1 |
| Emmick, JT; Kloner, RA; Mitchell, M | 1 |
| Aversa, A; Fabbri, A; Fini, M; Rosano, GM; Spera, G; Vitale, C | 1 |
| Hogan, MJ | 1 |
| Carson, C; Fredlund, P; Kuepfer, C; Murphy, A; Segal, S; Shabsigh, R | 1 |
| Costigan, TM; Emmick, JT; Jackson, G; Kloner, RA; Warner, MR | 1 |
| Bocchio, M; Desideri, G; Ferri, C; Francavilla, F; Francavilla, S; Mihalca, R; Necozione, S; Passaquale, G; Pelliccione, F | 1 |
| Kieback, A; Kloner, RA; Reffelmann, T | 1 |
| Jung, F; Leithäuser, B; Park, JW | 1 |
| Jackson, G | 1 |
9 review(s) available for tadalafil and Cardiovascular Diseases
| Article | Year |
|---|---|
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.
Topics: Cardiovascular Diseases; Erectile Dysfunction; Humans; Hypertension; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2020 |
Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Topics: Animals; Carbolines; Cardiovascular Diseases; Cardiovascular System; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2014 |
[Tadalafil for erectile dysfunction associated with cardiovascular diseases].
Topics: Carbolines; Cardiovascular Diseases; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Tadalafil | 2013 |
PDE-5 inhibitors: clinical points.
Topics: Cardiovascular Diseases; Drug Incompatibility; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride; Vasodilator Agents | 2015 |
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Topics: Allopurinol; Aspirin; Bromocriptine; Cardiovascular Diseases; Clonidine; Colesevelam Hydrochloride; Diabetes Mellitus; Drug Discovery; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Metabolic Syndrome; Piperazines; Tadalafil | 2016 |
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Topics: Algorithms; Carbolines; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Imidazoles; Impotence, Vasculogenic; Male; Men's Health; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Cardiovascular effects of tadalafil.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cardiovascular Diseases; Cardiovascular System; Drug Interactions; Erectile Dysfunction; Hemodynamics; Humans; Male; Nitric Oxide Donors; Phosphodiesterase Inhibitors; Tadalafil | 2003 |
Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Cardiovascular Diseases; Erectile Dysfunction; Humans; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Tadalafil | 2004 |
The cardiovascular safety of tadalafil.
Topics: Animals; Carbolines; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Erectile Dysfunction; Humans; Male; Tadalafil | 2008 |
6 trial(s) available for tadalafil and Cardiovascular Diseases
| Article | Year |
|---|---|
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.
Topics: Adult; Aged; Antihypertensive Agents; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Risk Factors; Tadalafil; Vasodilator Agents; Ventricular Dysfunction, Left | 2019 |
Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Risk Factors; Tadalafil; Vasodilator Agents | 2015 |
Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.
Topics: Aged; Brachial Artery; Carbolines; Cardiovascular Diseases; Endothelium, Vascular; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Risk; Tadalafil; Time Factors; Treatment Outcome; Vasodilation | 2005 |
Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.
Topics: Aged; Carbolines; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Double-Blind Method; Erectile Dysfunction; Female; Humans; Hyperlipidemias; Male; Middle Aged; Personal Satisfaction; Phosphodiesterase Inhibitors; Postoperative Complications; Prostatectomy; Sexual Partners; Surveys and Questionnaires; Tadalafil; Treatment Outcome; Vasodilator Agents | 2005 |
Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction.
Topics: Adult; Aged; Brachial Artery; Carbolines; Cardiovascular Diseases; Cyclic Nucleotide Phosphodiesterases, Type 5; Endothelial Cells; Erectile Dysfunction; Humans; Male; Middle Aged; Neovascularization, Physiologic; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Risk Factors; Tadalafil; Ultrasonography; Vasodilation | 2008 |
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Topics: Administration, Sublingual; Adult; Angina Pectoris; Blood Pressure; Carbolines; Cardiovascular Diseases; Dosage Forms; Drug Interactions; Erectile Dysfunction; Humans; Hypotension; Male; Nitrendipine; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil | 2008 |
12 other study(ies) available for tadalafil and Cardiovascular Diseases
| Article | Year |
|---|---|
The effect of cardiovascular morbidity on clinical response provided by tadalafil in patients with erectile dysfunction.
Topics: Carbolines; Cardiovascular Diseases; Double-Blind Method; Erectile Dysfunction; Humans; Male; Tadalafil; Treatment Outcome | 2021 |
Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Contraindications, Drug; Death, Sudden, Cardiac; Erectile Dysfunction; Forensic Medicine; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Risk; Sexual Behavior; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2021 |
[Safety of tadalafil in patients with cardiovascular comorbidities].
Topics: Cardiovascular Diseases; Cardiovascular System; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2019 |
[Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Topics: Carbolines; Cardiovascular Diseases; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Tadalafil | 2013 |
Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Cardiovascular Diseases; Cisplatin; Heart Rate; Male; Rats; Tadalafil | 2015 |
[Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers].
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Carbolines; Cardiovascular Diseases; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Risk Factors; Tadalafil | 2008 |
[5-phosphodiesterase inhibitors and cardiovascular risk].
Topics: Carbolines; Cardiovascular Diseases; Humans; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Risk Factors; Tadalafil | 2008 |
Management of erectile dysfunction in general practice.
Topics: Attitude of Health Personnel; Carbolines; Cardiovascular Diseases; Drug Prescriptions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Physician-Patient Relations; Piperazines; Practice Patterns, Physicians'; Primary Health Care; Purines; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Erectile dysfunction.
Topics: Blood Glucose; Carbolines; Cardiovascular Diseases; Cholesterol; Erectile Dysfunction; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2010 |
10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Topics: Carbolines; Cardiovascular Diseases; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Product Surveillance, Postmarketing; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2012 |
Erectile dysfunction and cardiovascular disease.
Topics: Adrenergic Antagonists; Carbolines; Cardiovascular Diseases; Contraindications; Erectile Dysfunction; Humans; Male; Nitrates; Nitric Oxide Donors; Tadalafil | 2005 |
Phosphodiesterase inhibition: erectile dysfunction is only part of the story.
Topics: Angiotensin II; Carbolines; Cardiovascular Diseases; Delayed-Action Preparations; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2002 |